Close Menu

Bio-Rad

The company filed to go public in March with plans to offer up to $60 million of its stock. 

Sales for Bio-Rad's Life Science segment were flat, but increased 9 percent on a currency-neutral basis.

Bio-Rad scientist Jennifer Berman explains how ddPCR can help detect the basic efficiency of CRISPR/Cas9 and other genome editing technologies and more.

The researchers' proof-of-concept paper published in PLOS One demonstrated a method that could lead to more haplotype analysis in genomic studies of diseases.

The suit alleges Bio-Rad fired its former general counsel for pursuing an investigation into bribery committed by the company's employees and agents in China. 

Both groups are making their detailed protocols available to researchers online.

Low-pass sequencing and digital PCR analysis of cell-free circulating tumor DNA could detect metastatic disease in primary breast cancer patients months before clinical diagnosis.

The company has established a streamlined workflow that customizes and automates key steps of the sample prep process.

The solutions will combine RainDance's digital droplet technology and single-molecule barcoding technology with PacBio's proprietary long-range DNA amplification technology.

On a currency-neutral basis, quarterly revenues increased about 1 percent compared to the same quarter last year.

Pages

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.